NCT00094094View on ClinicalTrials.gov

Anti-angiogenesis Agent AG-013736 in Patients With Advanced Non-Small Cell Lung Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

July 31, 2007

Study Completion Date

July 31, 2007

Conditions
Lung NeoplasmsCarcinoma, Non-small Cell Lung
Interventions
DRUG

axitinib

Axitinib (AG-013736) tablet administered orally at a dose of 5 milligrams (mg) twice daily (BID) in cycles of 4 weeks.

Trial Locations (11)

28203

Pfizer Investigational Site, Charlotte

37232

Pfizer Investigational Site, Nashville

53792

Pfizer Investigational Site, Madison

55422

Pfizer Investigational Site, Robbinsdale

55432

Pfizer Investigational Site, Fridley

55433

Pfizer Investigational Site, Coon Rapids

60068

Pfizer Investigational Site, Park Ridge

60637

Pfizer Investigational Site, Chicago

82131

Pfizer Investigational Site, Gauting

92612

Pfizer Investigational Site, Irvine

92868

Pfizer Investigational Site, Orange

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY